Follow
Chirantan Chatterjee, PhD, FRSA (Fellow, Royal Society of Arts, UK)
Chirantan Chatterjee, PhD, FRSA (Fellow, Royal Society of Arts, UK)
Professor of Development Economics, Innovation & Global Health, University of Sussex Business School
Verified email at sussex.ac.uk - Homepage
Title
Cited by
Cited by
Year
Does environmental regulation indirectly induce upstream innovation? New evidence from India
P Chakraborty, C Chatterjee
Research Policy 46 (5), 939-955, 2017
2302017
Regulation and welfare: evidence from paragraph IV generic entry in the pharmaceutical industry
L Branstetter, C Chatterjee, MJ Higgins
The RAND Journal of Economics 47 (4), 857-890, 2016
1392016
Gender and its rising role in modern Indian innovation and entrepreneurship
C Chatterjee, S Ramu
IIMB Management Review 30 (1), 62-72, 2018
562018
Ethical issues in health care sector in India
C Chatterjee, V Srinivasan
IIMB Management Review 25 (1), 49-62, 2013
522013
Strong medicine: Patent reform and the emergence of a research-driven pharmaceutical industry in India
A Arora, L Branstetter, C Chatterjee
NBER Conference on Location of Biopharmaceutical Activity, Boston, MA, 7-8, 2008
502008
Starving (or fattening) the golden goose?: generic entry and the incentives for early-stage pharmaceutical innovation
L Branstetter, C Chatterjee, MJ Higgins
National Bureau of Economic Research, 2014
462014
The consumer welfare implications of governmental policies and firm strategy in markets for medicines
C Chatterjee, K Kubo, V Pingali
Journal of Health Economics 44, 255-273, 2015
362015
Price control and access to drugs: The case of india’s malaria market
D Mohapatra, C Chatterjee
Working Paper. Cornell University, 2015
312015
Women’s disempowerment and preferences for skin lightening products that reinforce colorism: Experimental evidence from India
A Adbi, C Chatterjee, C Cortland, Z Kinias, J Singh
Psychology of Women Quarterly 45 (2), 178-193, 2021
27*2021
Can greater access to education be inequitable? New evidence from India’s Right to Education Act
C Chatterjee, EA Hanushek, S Mahendiran
National Bureau of Economic Research, 2020
272020
Mitigating regulatory impact: the case of partial price controls on metformin in India
A Bhaskarabhatla, C Chatterjee, P Anurag, E Pennings
Health policy and planning 32 (2), 194-204, 2017
272017
When the big one came: A natural experiment on demand shock and market structure in India's influenza vaccine markets
A Adbi, C Chatterjee, M Drev, A Mishra
Production and Operations Management 28 (4), 810-832, 2019
242019
Government health insurance and spatial peer effects: New evidence from India
C Chatterjee, R Joshi, N Sood, P Boregowda
Social Science & Medicine 196, 131-141, 2018
242018
Intellectual property regimes and wage inequality
S Bhattacharya, P Chakraborty, C Chatterjee
Journal of Development Economics 154, 102709, 2022
182022
Hit where it hurts: cartel policing using targeted sales and supply embargoes
A Bhaskarabhatla, C Chatterjee, B Karreman
The Journal of Law and Economics 59 (4), 805-846, 2016
182016
Stakeholder orientation and market impact: Evidence from India
A Adbi, A Bhaskarabhatla, C Chatterjee
Journal of business ethics 161, 479-496, 2020
162020
Strong medicine? Patent reform and the transformation of the Indian pharmaceutical industry
A Arora, L Branstetter, C Chatterjee, K Saggi
mimeo, 2009
152009
The role of physicians in prescribing irrational fixed-dose combination medicines in India
A Bhaskarabhatla, C Chatterjee
Social science & medicine 174, 179-187, 2017
132017
Innovation and internationalisation in the Indian software industry: Wipro–Going forward: Interview with Rishad Premji, Chief Strategy Officer, Wipro Limited
C Chatterjee
IIMB management Review 26 (1), 59-64, 2014
122014
Did India's price control policy for coronary stents create unintended consequences?
S Deo, H Tyagi, C Chatterjee, H Molakapuri
Social Science & Medicine 246, 112737, 2020
112020
The system can't perform the operation now. Try again later.
Articles 1–20